JPMorgan Chase & Co. Has $7.70 Million Stock Holdings in AxoGen, Inc. (NASDAQ:AXGN)

JPMorgan Chase & Co. boosted its position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 2,912.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 549,000 shares of the medical equipment provider's stock after purchasing an additional 530,775 shares during the period. JPMorgan Chase & Co. owned 1.25% of AxoGen worth $7,697,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AXGN. Quest Partners LLC grew its position in AxoGen by 23,066.7% during the third quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 2,076 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of AxoGen during the 3rd quarter valued at $56,000. Oppenheimer & Co. Inc. acquired a new position in shares of AxoGen in the third quarter worth $156,000. Quantbot Technologies LP acquired a new position in shares of AxoGen in the third quarter worth $165,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of AxoGen by 238.6% during the third quarter. BNP Paribas Financial Markets now owns 12,284 shares of the medical equipment provider's stock worth $172,000 after acquiring an additional 8,656 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com upgraded AxoGen from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $15.00.

AxoGen Stock Up 2.7 %

Shares of AxoGen stock traded up $0.49 during midday trading on Wednesday, reaching $18.73. 644,322 shares of the company's stock traded hands, compared to its average volume of 739,542. The company has a market cap of $824.27 million, a price-to-earnings ratio of -58.53 and a beta of 1.01. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $18.75. The company's 50 day simple moving average is $14.80 and its 200 day simple moving average is $12.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.